Patient [Name/ID Number] Important safety information, please carry this card with you at all times. Show it to any

Name of Epcoritamab treating physician (Epcoritamab).

Treating physician's emergency care phone number (after office hours)

SA-EPCOR-240001

Prepared in Jan 2024

Treating physician's phone number (during office hours)

Next of kin emergency contact information

Version 1.0 (July 2023)

Date of first dose of Epcoritamab



Tepkinly[™] (Epcoritamab) Patient Card

healthcare provider who sees you and when you go to any hospital. Tell any healthcare provider who sees you that you are being treated with Tepkinly™

your doctor or nurse. Be careful while driving, cycling, or using heavy or potentially dangerous machines. If you have any of the symptoms described on this card, you should avoid these activities.

If you get any side effects following your treatment with Epcoritamab, please talk to

Report side effects directly to AbbVie Biopharmaceuticals GmbH via Email: PV.MEA@abbvie.com. Hotline: 00966 55 828 2010 and National Pharmacovigilance Center Saudi Food and Drug Authority via SFDA Unified Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa/

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA.

Information for Patients
Epcoritamab may cause side effects which can be serious.
Call your doctor or get emergency help immediately if you have any of the following
symptoms:

Fever (38°C or higher)


Chills

Fast heartbeat

Headache

Dizziness or light-headedness

Difficulty/trouble breathing.





Seizures

Memory loss

•

antibody.

immune effector cell-associated neurotoxicity syndrome (ICANS) may occur, which may be serious if not treated promptly. • CRS may occur several hours or days after Epcoritamab administration, usually after the first full dose in Cycle 1. ICANS may occur several days or weeks after Epcoritamab administration. Contact the patient's treating physician immediately, for further information (contact details overleaf).

• This patient is being treated with Epcoritamab, a T-cell engaging bispecific

Following treatment with Epcoritamab, cytokine release syndrome (CRS) and

Information for Healthcare Providers